

Supplementary Information

(1*R*,4*S*,5*S*)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1*H*-tetrazol-5-yl)thio)cyclopent-2-en-1-ol

Milene A. G. Fortunato ¹, Filipa Siopa ^{1,*} and Carlos A. M. Afonso ^{1*}

1. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisboa, Portugal




Figure S1 ¹H-NMR spectrum of (1*R*,4*S*,5*S*)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1*H*-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.



	Parameter	Value
1	Solvent	D ₂ O
2	Temperature	288.8
3	Number of Scans	9847
4	Spectrometer Frequency	75.49
5	Nucleus	¹³ C




Figure S2 ¹³C-NMR spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.




Figure S3 HSQC spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (**3c**) in deuterium oxide.

FSMII #761 RT: 5.00 AV: 1 NL: 3.81E8
T: FTMS + p ESI Full ms [50.00-750.00]




Figure S4 HRMS spectrum of (1R,4S,5S)-5-((3-hydroxypropyl)amino)-4-((1-methyl-1H-tetrazol-5-yl)thio)cyclopent-2-en-1-ol (3c).